Anti-CCP antibodies and rheumatoid factor in systemic sclerosis:
Prevalence and relationships with joint manifestations

Wielosz, Ewa; Majdan, Maria; Dryglewska, Magdalena; Zwolak, Robert M.

doi:10.17219/acem/69921

Cited by 14 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Discussionsupporting

confidence: 89%

“…Further supporting this notion, serum CXCL12 levels were positively correlated with the titers of RF, which is produced by synovial B cells in response to the local environment in the rheumatoid joint. 43 Given that the association of RF positivity with SSc arthropathy is also reported in a previous study, 44 our current data suggest that CXCL12 is involved in the de- with the CXCL12-G801A, rather than CXCL12-G801A itself, to the altered levels of transcripts. Importantly, the expression of CXCL12 and CXCR4 is enhanced in endothelial cells of early edematous SScinvolved skin compared with those of healthy control skin, but their expressions are progressively decreased in parallel with disease duration irrespective of disease subtype.…”

Section: Discussionsupporting

confidence: 83%

See 1 more Smart Citation

Association of serum CXCL12 levels with arthropathy in patients with systemic sclerosis

et al. 2020

View full text Add to dashboard Cite

Aim Systemic sclerosis (SSc) is an autoimmune connective tissue disease, in which extensive fibrotic change and vasculopathy affect the skin and various internal organs. It also involves the joints, causing stiffness, arthralgia, and arthritis. Although arthropathy is commonly observed in SSc, its underlying mechanism remains unknown. CXCL12, also known as stromal cell derived factor 1, is associated with inflammation, mesenchymal cell recruitment, angiogenesis, and collagen production, and is implicated in the development of various joint diseases. To assess the potential contribution of CXCL12 to SSc development, we investigated the clinical association of serum CXCL12 levels in patients with SSc. Method We conducted a cross‐sectional analysis of 68 patients with SSc and 20 healthy controls recruited in a single center over 9 years. Serum CXCL12 levels were measured by enzyme‐linked immunosorbent assay. Results Serum CXCL12 levels were significantly higher in patients with SSc than in healthy controls (median 1554.0 pg/mL, 25th‐75th centiles 1313.0‐1914.0 pg/mL vs 967.4 pg/mL, 608.8‐1271.0 pg/mL, P < 0.001). Patients with SSc with elevated CXCL12 levels had significantly more cases of arthropathy than those with normal CXCL12 levels (85.7% vs 25.0%, P = 0.01). Furthermore, patients with SSc with elevated CXCL12 levels showed an increased trend in the prevalence of limited range of motion of the finger joints compared with those with normal CXCL12 levels (60.0% vs 18.6%, P =0 .07). Moreover, serum CXCL12 levels were significantly correlated with the titers of rheumatoid factor in patients with SSc (r = .41, P = 0.001). Conclusion Elevated serum CXCL12 levels may be related to the development of SSc arthropathy.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 83%

Association of serum CXCL12 levels with arthropathy in patients with systemic sclerosis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In fact, SSc-RA overlap is less common. The true rate of patients with SSc overlapped with RA is only 4.6%-6% (2,8) . In a research of 61 SSc patients, anti-CCP positive was observed only in patients with SSc-RA overlap (5) .…”

Section: Discussionmentioning

confidence: 94%

“…24-97% of patients with SSc developed arthritis during the course of the disease (5) . Anti-CCP antibodies and RF can be present in SSc patients, particularly in those with joint involvement, which may lead to misdiagnosis as RA on the early stage (2) . In fact, SSc-RA overlap is less common.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A rare case of Interstitial lung disease complicated by overlapping syndrome with obstructive ventilatory dysfunction as the first symptom

Liang

et al. 2021

MRHK

View full text Add to dashboard Cite

Interstitial lung disease is often a serious complication of connective tissue disease（CTD）, representing the first cause of death in CTD. However, there are few reports of SSc-RA overlap-associated interstitial pneumonia. Respiratory dysfunction as the first clinical manifestation is even rarely reported. We herein described a case of a male patient who developed significant respiratory dysfunction as the principal clinical sign for the past 6 months, plus newly developed skin thickening in bilateral upper limbs and pain and swelling of multiple joints for the past 6 weeks. Extensive immunological screening showed high titer of antinuclear antibodies(ANA), rheumatoid factor(RF), anti-cyclic peptide containing citrulline (anti-CCP)，and positive anti-Scl-70 antibody. Chest high resolution computed tomography(HRCT) was performed and hence ILD was confirmed. Pulmonary function test (PFT) revealed obstructive ventilatory dysfunction rather than restrictive ventilatory dysfunction. So bronchodilation test was performed and asthma was considered. Finally, after a multidisciplinary team (MDT) discussion, the diagnosis of asthma and ILD associated with SSc-RA overlap was established. It is important to note that CTD associated pulmonary interstitial fibrosis must be considered as the differential diagnosis of any newly diagnosed interstitial pulmonary disease. In addition, if patient with dyspnea is highly suspicious of pulmonary interstitial fibrosis, bronchodilation test is still needed to exclude asthma in order to avoid misdiagnosis.

show abstract

Neurological, cardiac, musculoskeletal, and renal manifestations of scleroderma along with insights into its genetics, pathophysiology, diagnostic, and therapeutic updates

Prajjwal,

Marsool,

Yadav

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

BackgroundScleroderma, also referred to as systemic sclerosis, is a multifaceted autoimmune condition characterized by abnormal fibrosis and impaired vascular function. Pathologically, it encompasses the persistent presence of inflammation, abnormal collagen buildup, and restructuring of blood vessels in various organs, resulting in a wide range of clinical symptoms. This review incorporates the most recent scientific literature on scleroderma, with a particular emphasis on its pathophysiology, clinical manifestations, diagnostic approaches, and treatment options.MethodologyA comprehensive investigation was carried out on numerous databases, such as PubMed, MEDLINE, Scopus, Web of Science, and Google Scholar, to collect pertinent studies covering diverse facets of scleroderma research.ResultsScleroderma presents with a range of systemic manifestations, such as interstitial lung disease, gastrointestinal dysmotility, Raynaud's phenomenon, pulmonary arterial hypertension, renal complications, neurological symptoms, and cardiac abnormalities. Serological markers, such as antinuclear antibodies, anti‐centromere antibodies, and anti‐topoisomerase antibodies, are important for classifying diseases and predicting their outcomes.DiscussionThe precise identification of scleroderma is crucial for promptly and correctly implementing effective treatment plans. Treatment approaches aim to improve symptoms, reduce complications, and slow down the progression of the disease. An integrated approach that combines pharmacological agents, including immunosuppressants, endothelin receptor antagonists, and prostanoids, with nonpharmacological interventions such as physical and occupational therapy is essential for maximizing patient care.ConclusionThrough the clarification of existing gaps in knowledge and identification of emerging trends, our goal is to improve the accuracy of diagnosis, enhance the effectiveness of therapeutic interventions, and ultimately enhance the overall quality of life for individuals suffering from scleroderma. Ongoing cooperation and creative research are necessary to advance the field and achieve improved patient outcomes and new therapeutic discoveries.

show abstract

Anti-CCP antibodies and rheumatoid factor in systemic sclerosis: Prevalence and relationships with joint manifestations

Cited by 14 publications

References 22 publications

Association of serum CXCL12 levels with arthropathy in patients with systemic sclerosis

Association of serum CXCL12 levels with arthropathy in patients with systemic sclerosis

A rare case of Interstitial lung disease complicated by overlapping syndrome with obstructive ventilatory dysfunction as the first symptom

Neurological, cardiac, musculoskeletal, and renal manifestations of scleroderma along with insights into its genetics, pathophysiology, diagnostic, and therapeutic updates

Contact Info

Product

Resources

About